CDMO Intertek announced that it has acquired a 29,000 sq ft facility in Melbourn, UK, which will allow the company to add to its GMP manufacturing capacity for inhaled drug products. The facility, which is located next to existing Intertek facilities in Melbourn, is expected to open by mid-2026 and will be expanded over the next 2 years.
According to Intertek, the expansion is driven by “the rapid growth of innovative drug development programs and rising client demand for expert support in the inhaled biologics space” and will support manufacturing of clinical supplies for multiple trials at the same time. In May 2025, the company announced a 6,000 sq ft expansion to add laboratory space at the Melbourn site in response to demand for services related to large molecules for inhalation.
Intertek Director of Pharmaceutical Development & Manufacturing Teresa Iley commented, “The landscape of inhaled and nasal drug development is evolving rapidly, demanding novel analytical techniques, innovative formulation technologies and integrated device solutions. Our new facility gives innovators the flexibility and technical resources to explore these frontiers, supporting everything from method development to clinical trial materials production in one collaborative environment.”
Executive VP, Europe, Middle East and Africa and Government and Trade Services, Ross McCluskey said, “This strategic expansion underscores Intertek’s commitment to providing robust analytical methods and scalable GMP clinical manufacturing, ensuring that clients can transition their novel technologies from proof of concept to late-stage clinical trials.”
Read the Intertek press release
